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ing by ElsAbstract Objectives: The aim of our study was to examine the efﬁciency of transient elastography
(TE) and Doppler indices, namely hepatic vein damping index (DI) and splenic artery pulsatility
index (SAPI) for evaluating the degree of hepatic ﬁbrosis in chronic hepatitis C (CHC) patients.
Patients and methods: One hundred and ten CHC patients were enrolled. Hepatic vein DI, SAPI,
and TE were performed to all patients before liver biopsy. Fibrosis was assessed on semi quantita-
tive scoring system (METAVIR score). We examine the efﬁciency of each test in differentiating dif-
ferent stages of hepatic ﬁbrosis and their diagnostic accuracy in predicting signiﬁcant ﬁbrosis FP 2
and cirrhosis.
Results: TE showed the best results in differentiating different stages of ﬁbrosis (p< 0.001), TE
had the best diagnostic accuracy for prediction of signiﬁcant ﬁbrosis and cirrhosis (AUROCs:
for FP 2 TE 0.92 vs. SAPI 0.74, DI 0.75; for cirrhosis TE 0.95 vs. DI 0.80, SAPI 0. 79). At albagoury Street, Heliopolis,
ail.com (M.I. Fahmy).
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112 M.I. Fahmy, H.M. Badrancut-off of 7 kPa, TE predicted signiﬁcant ﬁbrosis with 87% sensitivity and 86% speciﬁcity, it cor-
rectly classiﬁed 87% of patients vs. 71% for DI and 68% for SAPI. For prediction of cirrhosis, TE
at 16.5 kPa had 87% sensitivity and 91% speciﬁcity it correctly classiﬁed 90% of patients vs. 70%
for DI and 68% for SAPI.
Conclusion: TE is a non-invasive technique to accurately detect the presence of signiﬁcant ﬁbrosis
and cirrhosis in patients with CHC. While the ability of Doppler tests was limited.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.Table 1 Characteristics of the study group.
Characteristics Study group (n= 110)
Age, (y) 41 ± 9
Male sex, n (%) 84 (76%)
Body mass index 27.75 ± .37
Histological activity index <10/>10 7.163 ± 0.2895/15
Steatosis ve/+ve 92/18
Alanine aminotransferase 73.61 ± 4.24
Albumin, (gm/l) 4.299 ± 0.03
Bilirubin, (mg/dl) 0.715 ± 0.623
Hemoglobin, (g/dl) 13.79 ± 0.159
White blood cell counts, (·103/ml) 5.975 ± 0.145
Platelets, (·103/ml) 195 ± 4.657
Viral load, log10, (IU/ml) 785 ± 259
Fibrosis score (METAVIR), n (%)
F0–1 43 (39%)
F2 27 (25%)
18 (16%)
22 (20%)
F3
F41. Introduction
Hepatitis C virus infection, with an estimated prevalence of
more than 170 millions worldwide, is a major public health
care problem (1).
The prognosis and treatment of chronic liver disease de-
pend on the stage of liver ﬁbrosis (2). In chronic viral hepatitis,
the presence of signiﬁcant ﬁbrosis (FP 2) indicates the neces-
sity of antiviral therapies (3). Beyond being marker of injury,
liver ﬁbrosis appears to play a direct role in the pathogenesis
of hepatocellular dysfunction and portal hypertension (4).
Furthermore, reduced treatment response and tolerability to
antiviral may be encountered in cirrhotic patients (5). An accu-
rate assessment of the severity of hepatic ﬁbrosis is therefore
important for both diagnostic and therapeutic purposes (6).
Staging ﬁbrosis is an assessment of the combination of the
amount of ﬁbrosis and architecture disorganization (7). Liver
biopsy is the gold standard for assessment of the degree of
ﬁbrosis in chronic liver disease. However, liver biopsy is inva-
sive and costly and its interpretation requires an experienced
hepatopathologist. Although with precaution liver biopsy is
rather a safe procedure, between 0.6% and 5% of biopsy pa-
tients have had some complications. Since liver biopsy repre-
sent only about 1/50,000 of the liver tissue, inadequate
sample size and sampling error may lead to erroneous estima-
tion of the degree of ﬁbrosis. For these reasons, non-invasive
assessment of liver ﬁbrosis is a major objective that has
encouraged many new approaches (8).
Several Doppler indices have been proposed for patients
with chronic hepatitis C (CHC). It is known that the normal
triphasic hepatic vein (HV) Doppler waveform is transformed
into a biphasic or monophasic waveform in cirrhosis and por-
tal hypertension (9–14). However, the evaluation of HV wave-
form with a lack of quantitative value reduces its clinical value.
Assessment of damping index (DI) allows the quantiﬁcation of
the extent of the abnormal HV waveform (14).
Splenic impedance indices including splenic artery pulsatil-
ity index (SAPI) were associated with portal vein resistance,
signiﬁcant hepatic ﬁbrosis, and grade of esophageal varices
(15–17).
The latest technological advance in the setting of non-
invasive diagnosis is the measurement of liver stiffness (LS)
by mean of transient elastography (TE) (18), which is an ultra-
sound technique that uses pulse-echo ultrasound acquisitions
to measure liver stiffness in a volume of the liver that is
approximately 100 times bigger than liver biopsy, and thus
might be less prone than biopsy to sampling error. LS mea-
surement is a good method for the diagnosis of ﬁbrosis and cir-
rhosis irrespective of the cause of liver disease (19). LS
measured by a ﬁbroscan has been reported to correlate with
stage of liver ﬁbrosis in various liver disease (18–29).The aim of this work is to examine the efﬁciency of TE and
Doppler indices, namely (DI) and (SAPI) for evaluating the
degree of hepatic ﬁbrosis in CHC patients.
2. Patients and methods
The study was conducted at the Italian Hospital in Cairo and a
ﬁbroscan center in the period from March 2010 to February
2011. It included 110 newly diagnosed patients, who were po-
sitive for HCVAb and HCV-RNA by polymerase chain reac-
tion and who did not start interferon treatment. Patients
with other causes of chronic liver disease, bleeding tendency,
cardiac disease, and decompensate liver disease were not in-
cluded in our study group. The patient’s characteristics are
summarized in Table 1. All patients were subjected to the
following.
2.1. Color Doppler sonography of the middle hepatic vein and
splenic artery
Which was performed by one radiologist (to avoid interob-
server variability) using Toshiba Xario with convex probe
3.5 MHz. Doppler HV waveforms were recorded from the
mean of three repeated measurements. The maximum velocity
and minimum velocity of downward HV ﬂow were measured
and DI was calculated by the minimum velocity/maximum
velocity (30). The SAPI was measured automatically by the
machine by placing the sampling cursor in the branches of
the intrasplenic artery near the splenic hilum.
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Liver stiffness measurement was performed with the ﬁbroscan
apparatus (Echosens, Paris, France) within a week of liver
biopsy, according to the classical methodology (18). The mea-
surements were made on patients lying in dorsal decubitus with
the right arm in maximal abduction. The tip of the probe
transducer was covered with coupling gel and placed on the
skin, between the ribs at the level of the right lobe of the liver.
The operator, assisted by ultrasound time-motion and A-mode
images, located a portion of the liver free of large vascular
structures that was at least 6 cm thick. Once the measurement
area was located, the operator pressed the probe button to be-
gin an acquisition. Ten validated measurements were made on
each patient. The results were expressed in kilopascals (kPa).
Only procedures with 10 validated measurements and a success
rate of at least 60% (ratio of the number of successful acquisi-
tions over the total number of acquisitions) were considered
reliable. The median value was considered representative of
the liver elastic modulus.
2.3. Liver biopsy
Liver biopsy specimens composed of core >15 mm were as-
sessed according to METAVIR scoring system (31). Fibrosis
was staged on a 0–4 scale: F0, no ﬁbrosis; F1, portal ﬁbrosis
without septa; F2, portal ﬁbrosis and few septa; F3, numerous
septa without cirrhosis; and F4, cirrhosis.
2.4. Statistical analysis
Data was analyzed with SPSS version 13. Data was summa-
rized using mean and standard deviation (SD) for quantitative
variables and percent for qualitative variables. Comparisons
between quantitative variables were carried out using indepen-Table 2 Mean ± SD of the non-invasive tests in differe
F0–1 F2
TE (kPa) 5.8 ± 1.5b,c 8.9 ± 3.4a,c
DI 0.50 ± .22c 0.52 ± .21c
SAPI 0.91 ± .26 1.02 ± .21
TE, transient elastography; DI, damping index; SAPI, splen
a p< 0.05 vs. F0–1.
b p< 0.05 vs. F2.
c p< 0.05 vs. F3.
Figure 1 CHC patient with grade 1 ﬁbrosis: (A) TE was 4.4 kPa, (B
SAPI was 0.85.dent-sample T-test. One-way ANOVA (analysis of variable)
test with post hoc analysis were used in cases of more than
two quantitative variables. Receiver operator characteristic
(ROC) curves were constructed to evaluate the diagnostic
accuracy in predicting signiﬁcant ﬁbrosis and cirrhosis, areas
under ROC curves (AUROCs) of individual tests with 95%
conﬁdence intervals were calculated and compared (32). Kap-
pa test was used to test the agreement between different predic-
tors and METAVIR score of ﬁbrosis.
The results were considered statistically signiﬁcant when
p< 0.05.
3. Results
Patient’s characteristics are listed in Table 1.
Our results showed that TE, DI, and SAPI increase with
advances of hepatic ﬁbrosis, TE showed a statistically signiﬁ-
cant difference between different subgroups (p< 0.001), on
the other hand, DI showed no signiﬁcant difference between
(F0–1/F2) and (F3/F4). Regarding SAPI there was no
signiﬁcant difference between (F0–1/F2), (F2/F3), and (F3/
F4) (Table 2), (Figs. 1–4).
TE had a signiﬁcantly higher (AUROC) in predicting sig-
niﬁcant ﬁbrosis and cirrhosis than the Doppler indices
(p< 0.001), with no signiﬁcant difference found between DI
and SAPI (p> 0.05) (Fig. 5). TE also showed the highest de-
gree of agreement with the stage of hepatic ﬁbrosis according
to METAVIR score (k= 0.7).
At a cut-off point of P7 kPa, signiﬁcant ﬁbrosis could be
predicted with 91% certainty and excluded with 80% certainty
with a total validity of 87%. At a cut off point of P16.5 kPa,
hepatic cirrhosis could be predicted with 71% certainty and
excluded with 96% certainty with a total validity of 90%,
Doppler parameters showed low negative and positive predic-
tive values and low overall validity in predicting signiﬁcantnt ﬁbrosis stages.
F3 F4
15.5 ± 4.6a,b 23.1 ± 9.2a,b,c
0.74 ± .21a,b 0.81 ± .1a,b
1.14 ± .24a 1.3 ± .21a,b
ic artery pulsatility index.
) HV showed a biphasic waveform with a mean DI 0.37, and (C)
Figure 2 CHC patient with grade 2 ﬁbrosis: (A) TE was 7.6 kPa, (B) HV showed a triphasic waveform with a mean DI 0.5, and (C) SAPI
was 0.98.
Figure 3 CHC patient with grade 3 ﬁbrosis: (A) TE was 11.1 kPa, (B) HV showed a monophasic waveform pattern with a mean DI 0.64,
and (C) SAPI was 1.18.
Figure 4 CHC patient with cirrhosis: (A) TE was 21.3 kPa, (B) HV wave form showed monophasic waveform with a mean DI 0.77, and
(C) SAPI was 1.37.
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DI, each test excluded cirrhosis with a NPV of 91% and 95%,
respectively. Conversely, prediction of cirrhosis was much less
reliable with a PPV of 37% and 40%, respectively (Tables 3
and 4).
4. Discussion
The presence of signiﬁcant ﬁbrosis is considered a hallmark of
a progressive liver disease. Therefore, in clinical practice, the
differentiation between mild and no ﬁbrosis (F0–1) versus sig-
niﬁcant ﬁbrosis (FP 2) is of great importance.
The results of the present study showed that TE is the most
accurate method for predicting signiﬁcant ﬁbrosis and cirrho-
sis, with AUROCs of 0.92 and 0.95, respectively. Furthermore,
TE showed the highest degree of agreement with METAVIR
score (k= 0.7), a ﬁnding in keeping with other studies, where
AUROC ranged from 0.79 to 0.91 for prediction of signiﬁcantﬁbrosis (26,29,33–36), and ranged from 0.94 to 0.98 in predic-
tion of cirrhosis (19,33,34,37,38). This comes in partial agree-
ment with results of Degos et al. (39), who found that the
diagnostic accuracy of non-invasive tests was high for cirrho-
sis, but poor for signiﬁcant ﬁbrosis. But it stated among
non-invasive tests, ﬁbroscan ranks ﬁrst in diagnostic accuracy
especially when compared to biochemical tests, the diagnostic
accuracy of ﬁbroscan is not 100% as tissue abnormalities
independent of ﬁbrosis, such as edema and inﬂammation, cho-
lestasis and congestion, may impact ﬁbroscan. The risk of
overestimating liver stiffness values has been reported in the
case of alanine amniotransferse ﬂares in patients with acute
viral hepatitis or chronic hepatitis B as well as in cases of extra-
hepatic cholestasis (34,40–42). In our series, by inclusion crite-
ria none of the patients had hepatic congestion or extra hepatic
cholestasis.
The diagnostic accuracy of TE for prediction of signiﬁcant
ﬁbrosis and cirrhosis were signiﬁcantly higher than SAPI and
Figure 5 ROC curves of TE (ﬁbroscan), DI and SAPI in
predicting patients with signiﬁcant hepatic ﬁbrosis (FP 2) (A)
and cirrhosis (B), TE showed a signiﬁcantly higher AUROC than
DI and SAPI, while AUROC of DI and SAPI were comparable.
Table 3 Comparative performance of the noninvasive tests for pre
Cut-oﬀ point Sn Sp PPV
TE (kPa) 7 87% 86% 91%
DI 0.64 69% 74% 81%
SAPI 1 66% 72% 79%
Sn, sensitivity; sp, speciﬁcity; PPV, positive predictive value; NPV, negat
teristic curve.
Table 4 Comparative performance of the non invasive tests for pre
Cut-oﬀ point Sn Sp PPV
TE (kPa) 16.5 87% 91% 71%
DI 0.71 87% 65% 40%
SAPI 1.06 74% 67% 37%
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them (p> 0.05).
For predicting signiﬁcant hepatic ﬁbrosis, TE set at 7 kPa
resulted in 86% correctly classiﬁed cases, while for cirrhosis,
TE set at 16 kPa resulted in 90% correctly classiﬁed cases. Sim-
ilar cut-off level for predicting signiﬁcant ﬁbrosis was reported
in other studies (21,36), while other studies reported cut off le-
vel ranging from 5 to 9.1 (22,27,29,34,43). Different cut off le-
vel for cirrhosis were reported in other studies ranging from
11.6 to 26 kPa (19,21,22,24,27,29,34,36).
With the advance of hepatic ﬁbrosis, the portal resistance
increases, causing the increased outﬂow resistance of the sple-
nic artery. The decreased diastolic velocity of the splenic artery
results in increased splenic impedance indices (splenic artery
resistive index (SARI) and SAPI). The later which uses the
mean arterial velocity instead of the peak arterial velocity,
makes it more sensitive than SARI in detecting the waveform
changes on increased portal resistance (15). Previous studies
have shown that hepatic impedance indices (hepatic artery
resistive and pulsaitility indices) were correlated with the sever-
ity of hepatic ﬁbrosis, based on the assumption of distortion of
hepatic architecture and reduction of intrahepatic vascular
space (44,45).
In the current study SAPI as well as DI gave good result in
excluding cirrhosis, being suboptimal to modest in predicting
signiﬁcant ﬁbrosis and cirrhosis. Liu et al. (6) found a high
PPV for SAPI in predicating signiﬁcant ﬁbrosis (98%) but a
modest NPV (76%), both values were high in predicting cir-
rhosis (90%) and (97%), respectively. The suboptimal diag-
nostic power of SAPI in excluding the presence of signiﬁcant
ﬁbrosis could be explained by the subtle change of portal resis-
tance in mild to moderate hepatic ﬁbrosis.
Kim et al. (28) found a signiﬁcant positive correlation be-
tween hepatic veins DI and the grade of hepatic venous pres-
sure gradient. To our knowledge, this is the ﬁrst study to
examine a possible correlation between hepatic veins DI
and the severity of hepatic ﬁbrosis. In the current study DI
shows comparable results to SAPI, its low prediction power
could be attributed to hepatic fatty changes and the increase
of hepatic indices with age in healthy subjects (46), making
the indices less reliable in detecting the severity of hepatic
ﬁbrosis. In case of SAPI <1 and DI <0.64, another compli-
mentary test, such as ﬁbroscan should be performed to in-
crease diagnostic accuracy. However, we found that each ofdiction of signiﬁcant hepatic ﬁbrosis FP 2.
NPV Correctly classiﬁed AUROC Kappa
80% 87% 0.92 0.71
60% 71% 0.75 0.41
57% 68% 0.74 0.36
ive predictive value; AUROC, area under receiver operating charac-
diction of cirrhosis.
NPV Correctly classiﬁed AUROC Kappa
96% 90% 0.95 0.72
95% 70% 0.80 0.37
91% 68% 0.79 0.3
116 M.I. Fahmy, H.M. Badranthese tests was more suited for exclusion of cirrhosis than for
its prediction.
TE has certain advantages over Doppler indices, for it
measures liver stiffness in relation to elasticity, corresponding
to a genuine and intrinsic physical property of the liver paren-
chyma (7), and it provides more direct measurement of
ﬁbrosis, being highly reproducible and operator-independent
technique (29,33).
Because TE can be performed rapidly, painlessly and has
high patient acceptance, it might become a common way of
assessing ﬁbrosis in routine practice (47).5. Conclusions
An accurate and objective quantiﬁcation of hepatic ﬁbrosis is
essential to provide clinically useful information for the mon-
itoring of CHC progression and therapy. The performance
of Doppler indices was limited. The value of TE and the rela-
tion to tissue diagnosis in patients with CHC is promising and
needs further assessment. Applying this noninvasive test can
decrease the need for liver biopsy in staging of hepatic ﬁbrosis.
Further studies are needed to monitor disease progression.Conﬂict of interest
None.
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